• About us
• Contact

Advertisement

Person › Details

Ken Song (Candid Therapeutics Inc.)

Song, Ken (Candid Tx 202409 CEO + Co-Founder before RayzeBio + Metacrine + Ariosa Diagnostics + Venrock + McKinsey)

 

	Organisation	RayzeBio Inc. (Nasdaq: RYZB)
	Group	Bristol Myers Squibb (BMS) (Group)
	Product	Harmony™ Prenatal Test

Record changed: 2025-01-13

Advertisement

More documents for Ken Song

• [1] Bristol Myers Squibb Company. (12/26/23). "Press Release: Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio". Princeton, NJ & San Diego, CA....
• [2] RayzeBio, Inc.. (12/8/20). "Press Release: RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer". San Diego, CA....
• [3] RayzeBio, Inc.. (10/14/20). "Press Release: RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics". San Diego, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.